Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to 0.01%.

  • CorMedix's EBITDA Margin fell 200.0% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.37%, marking a year-over-year increase of 713400.0%. This contributed to the annual value of 41.25% for FY2024, which is 1351236600.0% down from last year.
  • Latest data reveals that CorMedix reported EBITDA Margin of 0.01% as of Q3 2025, which was down 200.0% from 0.01% recorded in Q2 2025.
  • In the past 5 years, CorMedix's EBITDA Margin registered a high of 192858.54% during Q2 2023, and its lowest value of 100446.94% during Q3 2022.
  • Over the past 5 years, CorMedix's median EBITDA Margin value was 28.73% (recorded in 2024), while the average stood at 1666.4%.
  • Per our database at Business Quant, CorMedix's EBITDA Margin soared by 2000000000bps in 2023 and then crashed by -1928582600bps in 2024.
  • Over the past 5 years, CorMedix's EBITDA Margin (Quarter) stood at 13829.39% in 2021, then plummeted by -99bps to 27513.23% in 2022, then skyrocketed by 370bps to 74358.67% in 2023, then tumbled by -100bps to 57.44% in 2024, then skyrocketed by 100bps to 0.01% in 2025.
  • Its EBITDA Margin was 0.01% in Q3 2025, compared to 0.01% in Q2 2025 and 0.02% in Q1 2025.